{
    "nctId": "NCT06418139",
    "briefTitle": "Association of Pembrolizumab Infusion Time and Efficacy in Patients With Non-metastatic Triple-negative Breast Cancer (TNBC) Treated With Neoadjuvant Chemotherapy and Immunotherapy",
    "officialTitle": "Etude de l'Effet de l'Horaire de Perfusion de l'immunoth\u00e9rapie Sur la r\u00e9ponse et la toxicit\u00e9 Des Traitements Chez Les Patientes Atteintes de Cancer du Sein Triple n\u00e9gatif \u00e0 Haut Risque trait\u00e9 Par chimioth\u00e9rapie n\u00e9oadjuvante et Pembrolizumab",
    "overallStatus": "NOT_YET_RECRUITING",
    "conditions": "Non-Metastatic Breast Carcinoma",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 450,
    "primaryOutcomeMeasure": "Residual cancer burden class (RCB)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Female sex\n* Age \u2265 18 years-old\n* Previously untreated histologically proven triple-negative breast cancer (RE \\< 10%, RP \\< 10%, Her-2 negative)\n* No metastatic\n* Having at least one injection of pembrolizumab associated with chemotherapy\n* Pembrolizumab injection schedule correctly reported by the nurse in charge of the patient\n\nExclusion Criteria:\n\n\u2022 Metastatic disease",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}